Patents Issued in September 10, 2019
-
Patent number: 10406115Abstract: Described are pressure-sensitive adhesive polymers (PSAs) useful, for example, for application to the skin, such as in the field of transdermal drug delivery. The PSAs include polar groups modeled on one or more polar portions of skin lipids, which contribute to good skin adhesion properties. Methods of making the PSAs, compositions comprising them, and methods of making and using them also are provided.Type: GrantFiled: February 5, 2016Date of Patent: September 10, 2019Assignee: NOVEN PHARMACEUTICALS, INC.Inventors: Jilin Zhang, Jun Liao, Puchun Liu, Steven Dinh
-
Patent number: 10406116Abstract: Described are pressure-sensitive adhesive polymers (PSAs) useful, for example, for application to the skin, such as in the field of transdermal drug delivery. The PSAs include polar groups modeled on one or more polar portions of skin lipids, which contribute to good skin adhesion properties. Methods of making the PSAs, compositions comprising them, and methods of making and using them also are provided.Type: GrantFiled: August 3, 2016Date of Patent: September 10, 2019Assignee: NOVEN PHARMACEUTICALS, INC.Inventors: Jilin Zhang, Jun Liao, Puchun Liu, Steven Dinh
-
Patent number: 10406117Abstract: The present invention is a water-soluble form of lipophilic molecules contained in liposomes. In one embodiment, the lipophilic molecule is crystalline lutein and the lutein-loaded liposomes are included in pharmaceutical products, medical devices, and dietary supplements industry, with potential for chewable tablets, fortification of beverages, effervescent tablets, uncoated tablets, nutritional bars, and functional foods in addition to cosmetic industry.Type: GrantFiled: February 13, 2017Date of Patent: September 10, 2019Assignee: KEMIN INDUSTRIES, INC.Inventor: Diogo de Sousa Martins
-
Patent number: 10406118Abstract: Inorganic anions nitrate and nitrite influence metabolic rate and glucose homeostasis. Infusion of nitrite iv caused an acute drop in resting energy expenditure (oxygen consumption) and nitrate, when given perorally, caused a drop in oxygen consumption during exercise and a depression of the increase in blood glucose observed after an oral glucose tolerance test. The doses of nitrate and nitrite did not cause any detectable change in methemoglobin levels of blood. Also, nitrate and nitrite did not alter lactate levels in blood. This discovery provides useful treatments to regulate the energy expenditure and glucose homeostasis of a mammal by administration of inorganic nitrite and/or nitrate.Type: GrantFiled: February 26, 2008Date of Patent: September 10, 2019Inventors: Jon Lundberg, Eddie Weitzberg
-
Patent number: 10406119Abstract: Compositions and pharmaceutical compositions including a dendrimer-resveratrol complex and methods for making and using the compositions are described herein. Methods of treating cancer, cardiovascular disease, cardiac failure, diabetes, Alzheimer's disease, Parkinson's disease and other brain diseases, fatty liver disease, obesity, cataracts, osteoporosis, muscle wasting, sleep disorders, acoustic trauma, inflammatory disease, psoriasis, arthritis, colitis, aging, viral disease, reproductive disease, and skin conditions or disorders including administering a therapeutically effective amount of the compositions to a subject in need are also provided. The compositions may be topically applied to skin or mucous membranes.Type: GrantFiled: December 5, 2017Date of Patent: September 10, 2019Assignee: Concordia UniversityInventors: Abhay Singh Chauhan, Eric Andrew Newenhouse, Armin Henry Gerhardt
-
Patent number: 10406120Abstract: The present invention provides methods for treating glomerulosclerosis such as focal segmental glomerulosclerosis (FSGS) or glomerulonephritis such as immunoglobulin A nephropathy (IgAN) by cyclohexenone compounds.Type: GrantFiled: March 2, 2016Date of Patent: September 10, 2019Assignee: Golden Biotechnology CorporationInventors: Sheng-Yung Liu, San-Bao Hwang
-
Patent number: 10406121Abstract: Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(?)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(?)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.Type: GrantFiled: December 21, 2017Date of Patent: September 10, 2019Assignee: National University Corporation Chiba UniversityInventor: Kenji Hashimoto
-
Patent number: 10406122Abstract: A method of treating pain, e.g., acute post-operative pain, by administering to a human patient(s) a therapeutically effective dose of tramadol intravenously over a prolonged time period is disclosed. In certain embodiments, the dose is intravenously administered in a time period from about 10 minutes to about 3 hours, preferably from about 10 minutes to about 30 minutes. In other embodiments, intravenous doses are administered at suitable time intervals over a time period from about 3 hours to 48 hours.Type: GrantFiled: May 7, 2018Date of Patent: September 10, 2019Assignee: Revogenex Ireland Ltd.Inventors: S. George Kottayil, Jeffrey H. Ping
-
Patent number: 10406123Abstract: Methods and compositions utilizing 2-aminoindan derivatives collectively represented by Formula I as described and defined in the specification for regulating binge behavior, particularly binge drinking, are disclosed.Type: GrantFiled: October 23, 2018Date of Patent: September 10, 2019Inventor: Ezekiel Golan
-
Patent number: 10406124Abstract: A therapeutic agent comprising a cell binding agent which binds the Receptor for Advanced Glycation End (RAGE) products linked to an anti-cancer drug, for use in the treatment of gynaecological cancer, endometriosis or polycystic ovary syndrome. Novel cell binding agents, pharmaceutical compositions and methods are also described and claimed.Type: GrantFiled: October 21, 2015Date of Patent: September 10, 2019Assignee: Swansea UniversityInventors: Robert Conlan, Deyarina Gonzalez
-
Patent number: 10406125Abstract: The present invention relates to a combination comprising an aminothiolester compound or a pharmaceutically acceptable salt thereof, in particular the S-methyl 4-(dimethylamino)-4-methylpent-2-ynethioate or a pharmaceutically acceptable salt thereof, and more particularly the 4-(Dimethylamino)-4-methyl-2-pentynethioic acid S-methyl ester fumarate, and a compound able to increase H2O2 level in cancer cells of a subject, in particular for use for the treatment of cancer in a subject, wherein cancer cells of said subject do not overproduce H2O2 in comparison to a control value and have a level of GSH below 5 nmol for 25000 cells.Type: GrantFiled: October 14, 2016Date of Patent: September 10, 2019Assignee: ADVANCED BIODESIGNInventors: Ismail Ceylan, Gerry Quash, Mileidys Perez-Alea, Guillaume Martin
-
Patent number: 10406126Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.Type: GrantFiled: January 29, 2019Date of Patent: September 10, 2019Assignee: Eisai R&D Management Co., Ltd.Inventors: Keigo Tanaka, Tasuku Ishida, Masayuki Miyano, Raku Shinkyo
-
Patent number: 10406127Abstract: Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration.Type: GrantFiled: July 24, 2015Date of Patent: September 10, 2019Assignee: LAURENT PHARMACEUTICALSInventors: Aimesther Betancourt, Marc Lemieux, Roch Thibert
-
Patent number: 10406128Abstract: The present invention discloses novel agents and methods for diagnosis and treatment of colon cancer. Also disclosed are related arrays, kits, and screening methods.Type: GrantFiled: January 4, 2019Date of Patent: September 10, 2019Assignee: The Rockefeller UniversityInventors: Sohail F. Tavazoie, Jia Min Loo
-
Patent number: 10406129Abstract: Methods of suppressing cyclooxygenase activity or reducing platelet aggregation of a mammal in need thereof by administering to a mammal in need thereof an effective amount of trans-resveratrol and arginine for a period of at least two weeks.Type: GrantFiled: September 1, 2017Date of Patent: September 10, 2019Inventors: Shil Kothari, Gary Troxel
-
Patent number: 10406130Abstract: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of reducing or preventing sdLDL oxidation in a subject, the method comprising administering to the subject a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.Type: GrantFiled: January 25, 2017Date of Patent: September 10, 2019Assignee: Amarin Pharmaceuticals Ireland LimitedInventor: Richard Preston Mason
-
Patent number: 10406132Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.Type: GrantFiled: March 8, 2016Date of Patent: September 10, 2019Assignee: The Children's Mercy HospitalInventors: Susan Abdel-Rahman, Barry L. Preuett, Steven J. Leeder
-
Patent number: 10406133Abstract: The present invention provides compounds of formula (I), and pharmaceutical compositions thereof.Type: GrantFiled: September 28, 2018Date of Patent: September 10, 2019Assignee: Alkermes Pharma Ireland LimitedInventors: Tarek A. Zeidan, Scott Duncan, Christopher P. Hencken, Thomas Andrew Wynn, Carlos N. Sanrame
-
Patent number: 10406134Abstract: The invention generally relates in part to methods of effecting weight loss and/or improving glucose tolerance in a patient in need thereof, comprising administering a MetAP2 inhibitor.Type: GrantFiled: April 11, 2017Date of Patent: September 10, 2019Assignees: Zafgen, Inc., Vanderbilt UniversityInventors: Thomas E. Hughes, James E. Vath, Alan D. Cherrington
-
Patent number: 10406135Abstract: Compositions comprising isosorbide monoesters and alcohols comprising at least one aromatic group What are described are compositions comprising a) one or more compounds of the formula (I) in which R is a straight-chain or branched saturated alkyl group having 5 to 11 carbon atoms or a straight-chain or branched mono- or polyunsaturated alkenyl group having 5 to 11 carbon atoms, and b) one or more alcohols comprising at least one aromatic group. The compositions are distinguished in particular by an advantageous antimicrobial activity.Type: GrantFiled: July 31, 2012Date of Patent: September 10, 2019Assignee: Clariant International Ltd.Inventors: Maurice Frederic Pilz, Peter Klug, Franz-Xaver Scherl, Joerg Grohmann
-
Patent number: 10406136Abstract: The present invention relates to a composition for suppressing neuraminidase activity comprising a geranylated flavonoid derived from Paulownia tomentosa as an active ingredient. The Paulownia tomentosa extract and the geranylated flavonoid isolated therefrom exhibit an effect in significantly suppressing neuraminidase, which is an enzyme that plays an important role in the occurrence of pathogenic viral and bacterial infections and of the inflammation that accompanies such infection, and thus the Paulownia tomentosa extract or the geranylated flavonoid isolated therefrom can advantageously be used as an active ingredient in a composition for inhibiting neuraminidase activity.Type: GrantFiled: July 25, 2014Date of Patent: September 10, 2019Assignees: INDUSTRY-ACADEMIC COOPERATION FOUNDATION GYEONGSANG NATIONAL UNIVERSITY, GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGYInventors: Ki Hun Park, Soo Hyun Eom, Young Bae Ryu, Jung Keun Cho
-
Patent number: 10406137Abstract: Polymorph forms of 4-trifluoromethyl-N-(3,3a,4,4a,5,5a,6,6a-octahydro-1,3-dioxo-4,6-ethenocycloprop[f]isoindol-2(1H)-yl)-benzamide are disclosed as well as their methods of synthesis and pharmaceutical compositions.Type: GrantFiled: July 2, 2018Date of Patent: September 10, 2019Assignee: Siga Technologies Inc.Inventors: Shanthakumar R. Tyavanagimatt, Melialani A.C.L.S. Anderson, William C. Weimers, Dylan Nelson, Tove′ C. Bolken, Dennis E. Hruby, Michael H. O'Neill, Gary Sweetapple, Kelley A. McCloughan
-
Patent number: 10406138Abstract: The present invention is directed to a combination comprising a proteasome inhibitor and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.Type: GrantFiled: May 21, 2018Date of Patent: September 10, 2019Assignee: Purdue Pharmaceutical Products L.P.Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
-
Patent number: 10406139Abstract: The invention provides derivatives of cyclopamine having the following formula:Type: GrantFiled: March 27, 2018Date of Patent: September 10, 2019Assignee: Infinity Pharmaceuticals, Inc.Inventors: Brian Austad, Mark L. Behnke, Alfredo C. Castro, Michael J. Grogan, Somarajannair Janardanannair, Andre Lescarbeau, Stephane Peluso, Andre B. Charette, Martin R. Tremblay
-
Patent number: 10406140Abstract: Provided is a compound which is useful as an AMPK activator, represented by formula: wherein the symbols are defined in the specification.Type: GrantFiled: May 19, 2017Date of Patent: September 10, 2019Assignee: SHIONOGI & CO., LTD.Inventors: Yuusuke Tamura, Toshihiro Wada
-
Patent number: 10406141Abstract: The present invention provides a compound capable of being used as an active ingredient of an anti-cancer agent. To provide an anti-cancer agent with few side effects, an object of the present invention is to provide a compound capable of selectively inhibiting the target, i.e., DOCK1, or a salt thereof. The pyridinone compound of the present invention is represented by Formula (1): wherein R1 and R2 are the same or different, and each represents C1-6 alkyl; and R3 is a group represented by, for example, Formula (3) below: wherein R5 in the group represented by Formula (3) is hydrogen.Type: GrantFiled: February 26, 2016Date of Patent: September 10, 2019Assignee: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATIONInventors: Yoshinori Fukui, Takehito Uruno, Motomu Kanai, Shigeki Matsunaga, Takahiro Shirai, Shigeyuki Yokoyama, Teruki Honma, Mutsuko Niino, Daisuke Takaya
-
Patent number: 10406142Abstract: 1H-Imidazo[4,5-c]quinolin-4-amines substituted at the 1-position with a substituent bearing a hydrazinobenzamide or hydrazinonicotinamide, a salt thereof, or a protected hydrazinobenzamide or hydrazinonicotinamide and conjugates made from such compounds are disclosed. Pharmaceutical compositions containing the compound or the conjugate, methods of making a conjugate, and methods of use of the compounds or conjugates as immunomodulators for inducing cytokine biosynthesis in an animal and for vaccinating an animal are also disclosed.Type: GrantFiled: March 6, 2017Date of Patent: September 10, 2019Assignee: 3M lnnovative Properties CompanyInventor: Paul D. Wightman
-
Patent number: 10406143Abstract: Provided are in vitro and in vivo methods for determining whether a patient with Fabry disease will respond to treatment with a specific pharmacological chaperone.Type: GrantFiled: May 8, 2018Date of Patent: September 10, 2019Assignee: Amicus Therapeutics, Inc.Inventors: David J. Lockhart, Jeff Castelli
-
Patent number: 10406144Abstract: Compounds of formula (I) or (II) can modulate the activity of S1P receptors.Type: GrantFiled: June 27, 2018Date of Patent: September 10, 2019Assignee: BIOGEN MA INC.Inventors: Jermaine Thomas, Sha Mi, Edward Yin-Shiang Lin, Guo Zhu Zheng, Bin Ma, Richard D. Caldwell, Kevin M. Guckian, Gnanasambandam Kumaravel
-
Patent number: 10406145Abstract: This invention provides an isolated compound having the structure: or a salt thereof. The invention also provides for a process for preparing 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-4-ol, 1-(3,3-bis(3-(methylsulfonyl)phenyl)propyl)-4-(3-(methylsulfonyl) phenyl)piperidone, 1,4-bis((3-(1-propylpiperidin-4-yl)phenyl)sulfonyl)butane, (3R,4S)-4-(3-(methylsulfonyl)phenyl)-1-propylpiperidin-3-ol, 4-(3-(methylsulfonyl)phenyl)-1-propylpiperidine 1-oxide, 1-(2-methylpentyl)-4-(3-(methylsulfonyl)phenyl)piperidine, 4-(3-(methylsulfinyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine, and 4-(3-(methylsulfonyl)phenyl)-1-propyl-1,2,3,6-tetrahydropyridine. This invention also provides an impurity or a salt thereof for use, as a reference standard to detect trace amounts of the impurity in a pharmaceutical composition comprising pridopidine or a pharmaceutically acceptable salt thereof.Type: GrantFiled: October 3, 2018Date of Patent: September 10, 2019Assignee: PRILENIA NEUROTHERAPEUTICS LTD.Inventors: Malle Schmidt, Malle Päri, Marit Laos, Ants Maasalu, Kalle Kaljuste
-
Patent number: 10406146Abstract: The present invention provides a heterocyclic compound having a HDAC inhibitory action, and useful for the treatment of inflammatory disease and the like, and a medicament comprising the compound. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.Type: GrantFiled: August 24, 2016Date of Patent: September 10, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Kaieda, Naoki Ishii, Hiroshi Nara, Masato Yoshikawa, Masaki Daini
-
Patent number: 10406147Abstract: This invention is directed to derivatives of piperidine-2,6-dione, or their organic or inorganic salts thereof, a methods of synthesis of these derivatives, and their application as active pharmaceutical ingredient as inhibitors of TNF? releasing in cells, the derivative of piperidine-2,6-dione being of the general formula (I): wherein n represents 1, 2, 3, 4, 5 or 6; R1 represents from one to four of the same or different substituents selected from F, Cl, Br, C1-4 alkyl, OH, OC1-4 alkyl, NO2, NHC(O)C1-4 alkyl, NH2, NH(C1-4 alkyl), N(C1-4 alkyl)2; R2 represents OR3, NR3R4, N(R3)COR4, O2CR5; R3 and R4 represent independently and at each occurrence H or C1-4 alkyl; R5 represents CHR6NR7R8, CHR6NR9C(O)CHR10NR7R8, a heterocycle W or CHR6NR9C(O)W; R6, R9, R10 represent independently and at each occurrence H, or C1-4 alkyl; R7 and R8 represent independently and at each occurrence H, C1-4 alkyl, or R7 and R8 taken together represent 1,3-propylene, 1,4-butylene, 1,5-pentylene, or 1,6-hexylene; W represents four-mType: GrantFiled: November 20, 2018Date of Patent: September 10, 2019Assignee: Tianjin Hemay Bio-Tech Co., Ltd.Inventor: Hesheng Zhang
-
Patent number: 10406148Abstract: The invention relates to methods of treating ocular diseases and certain respiratory diseases using the compound 5-ethyl-2-fluoro-4-(3-(5-(1-methylpiperidin-4-yl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-2-yl)-1H-indazol-6-yl)phenol or a pharmaceutically-acceptable salt thereof.Type: GrantFiled: April 30, 2018Date of Patent: September 10, 2019Assignee: THERAVANCE BIOPHARMA R&D IP, LLCInventors: Melanie A. Kleinschek, Glenn D. Crater
-
Patent number: 10406149Abstract: A novel technique with which it is possible to suppress chemical degradation of a compound represented by general formula (1) or a salt thereof in an aqueous liquid formulation containing a compound represented by general formula (1) or a salt thereof. A method for suppressing the generation of a compound represented by general formula (2) or a salt thereof including containing a compound represented by general formula (1) or a salt thereof and a magnesium compound in an aqueous liquid formulation.Type: GrantFiled: June 2, 2016Date of Patent: September 10, 2019Assignee: KYORIN PHARMACEUTICAL CO., LTD.Inventors: Wataru Minagawa, Hitoshi Kozuka, Mizuho Shibata, Takahiro Goto, Chifuyu Toriumi, Norihiro Kanayama
-
Patent number: 10406150Abstract: The invention provides a method for treatment of primary progesterone receptor-negative (PR?) endometrial cancer comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a progesterone receptor (PR) agonist. The invention further provides a method for treatment of a primary estrogen receptor-negative (ER?) breast cancer, comprising administering (i) cridanimod or a salt or an ester thereof and (ii) a selective estrogen receptor modulator (SERM) or a selective estrogen receptor down-regulator (SERD). Also provided are compositions related to the above methods.Type: GrantFiled: March 31, 2017Date of Patent: September 10, 2019Assignee: Lipoxen Technologies LimitedInventors: Dmitry Genkin, Kirill Surkov
-
Patent number: 10406151Abstract: The present invention provides a method of inducing autophagy, the method including administering to a subject an effective amount of a pyrroloquinoline quinone compound or a salt thereof.Type: GrantFiled: November 20, 2017Date of Patent: September 10, 2019Assignee: MITSUBISHI GAS CHEMICAL COMPANY, INC.Inventor: Kazuto Ikemoto
-
Patent number: 10406152Abstract: The present disclosure provides acetate salts of buprenorphine, and its anhydrates, solvates, hydrates, and crystalline forms thereof, where the acetate salts of buprenorphine are essentially free of impurities. The disclosure further provides method of preparing the acetate salts, buprenorphine free base prepared from the acetate salts, other salts prepared from the free base, and pharmaceutical compositions thereof essentially free of impurities.Type: GrantFiled: March 9, 2016Date of Patent: September 10, 2019Assignee: RHODES TECHNOLOGIESInventors: C. Frederick M. Huntley, Erik Wayne Kataisto, Helge Alfred Reisch, Archana Sharma
-
Patent number: 10406153Abstract: The invention is directed to processes for the preparation of benzhydrocodone hydrochloride. More particularly, the invention is directed to processes for a one-pot synthesis of benzhydrocodone hydrochloride of improved yield and/or purity.Type: GrantFiled: August 31, 2017Date of Patent: September 10, 2019Assignee: Noramco, Inc.Inventors: Wen-Chun Zhang, Bruce P. Johnson
-
Patent number: 10406154Abstract: The disclosure generally relates to tamper-resistant transdermal dosage forms. The dosage forms can comprise an active agent and more than one antagonist reservoir.Type: GrantFiled: July 2, 2018Date of Patent: September 10, 2019Assignee: Clexio Biosciences Ltd.Inventors: John Tang, Prashant Patel, Bhavik Patel, Longchun Yu
-
Patent number: 10406155Abstract: This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a ?1 receptor agonist that also has NMDA antagonist activity.Type: GrantFiled: July 16, 2018Date of Patent: September 10, 2019Assignee: Concert Pharmaceuticals, Inc.Inventors: Philip B. Graham, I. Robert Silverman
-
Patent number: 10406156Abstract: This application discloses a composition comprising an amiloride and/or an amiloride analog which can be used for reducing nerve injury or nervous system injury in a subject. The formulation of such composition is also disclosed. The application further directs to methods for treating nerve injury or nervous system injury by administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising amiloride, an amiloride analog or a pharmaceutically acceptable salt thereof.Type: GrantFiled: March 30, 2017Date of Patent: September 10, 2019Assignee: MOREHOUSE SCHOOL OF MEDICINEInventors: Zhigang Xiong, Roger P. Simon
-
Patent number: 10406157Abstract: Disclosed is a compound of Formula 1, and a pharmaceutically acceptable salt thereof. This disclosure also relates to materials and methods for preparing the compound of Formula 1, to pharmaceutical compositions which contain it, and to its use for treating diseases, disorders, and conditions associated with GPR6.Type: GrantFiled: June 15, 2018Date of Patent: September 10, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Jason W. Brown, Stephen Hitchcock, Maria Hopkins, Shota Kikuchi, Holger Monenschein, Holly Reichard, Kristin Schleicher, Huikai Sun, Todd Macklin
-
Patent number: 10406158Abstract: The present invention relates to, inter alia, combinations, methods, compositions, and oral dosage forms of a FAK inhibitor and a MEK inhibitor, for treating abnormal cell growth (e.g., cancer).Type: GrantFiled: April 2, 2018Date of Patent: September 10, 2019Assignee: Verastem, Inc.Inventors: Jonathan A. Pachter, Winnie Tam, Qunli Xu
-
Patent number: 10406159Abstract: Provided herein are methods for preparing stable solutions containing 5-methyltetrahydrofolate (MTHF). Also provided herein are stable compositions containing calcium 5-methyltetrahydrofolate (MTHF-Ca).Type: GrantFiled: January 26, 2016Date of Patent: September 10, 2019Assignee: La Vita Compounding PharmacyInventors: Debra K. Hubers, Christine A. Givant
-
Patent number: 10406160Abstract: An injectable depot formulation includes a biocompatible polymer, an organic solvent combined with the biocompatible polymer to form a viscous gel, and a small molecule drug incorporated in the viscous gel such that the formulation exhibits an in vivo release profile having a Cmax to Cmin ratio of less than 200 and a lag time less than 0.2.Type: GrantFiled: July 24, 2018Date of Patent: September 10, 2019Assignee: INDIVIOR UK LIMITEDInventors: Andrew S. Luk, Gunjan H. Junnarkar, Guohua Chen
-
Patent number: 10406161Abstract: A risperidone sustained release microsphere formulation is provided. The microsphere formulation comprise risperidone or 9-hydroxy risperidone or salts thereof, and a polymer blend having a first uncapped lactide-glycolide copolymer and a second uncapped lactide-glycolide copolymer, in which the first uncapped lactide-glycolide copolymer is a copolymer with a high intrinsic viscosity and the second uncapped lactide-glycolide copolymer is a copolymer with a low intrinsic viscosity. The sustained release microsphere formulation according to an embodiment of the present disclosure is suitable for large-scale industrialized production with improved stability, the in vivo release behavior of which will not change after long-term storage.Type: GrantFiled: September 27, 2018Date of Patent: September 10, 2019Assignees: SHANDONG LUYE PHARMACEUTICAL CO., LTD., NANJING LUYE PHARMACEUTICAL CO., LTD.Inventors: Kaoxiang Sun, Rongcai Liang, Qilin Wang, Wenyan Wang, Wanhui Liu, Youxin Li
-
Patent number: 10406162Abstract: The present invention relates to * combinations of: ? component A: one or more 2,3-dihydroimidazo[1,2-c]quinazoline compounds of general formula (A1) or (A2), or a physiologically acceptable salt, solvate, hydrate or ? stereoisomer thereof; ? component B: one or more substituted 5-(1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]-triazin-4-amine compounds of general formula (B), or a physiologically acceptable salt, solvate, hydrate or stereoisomer thereof; ? in which optionally some or all of the components are in the form of a pharmaceutical formulation which is ready for use to be administered simultaneously, concurrently, separately or sequentially, ? dependently of one another by the oral, intravenous, topical, local installations, ? intraperitoneal or nasal route; * use of such combinations for the preparation of a medicament for the treatment or prophylaxis of a cancer; * a kit comprising such a combination; * use of biomarkers which is the loss of tumor suppressor PTEN or FBXW7, for predicting the sensitiviType: GrantFiled: March 7, 2016Date of Patent: September 10, 2019Assignee: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Ningshu Liu, Carol Pena, Michael Jeffers, Isabelle Genvresse
-
Patent number: 10406163Abstract: This invention generally provides compounds, pharmaceutical compositions, and methods for their use, which include methods that result in increased expression in an Atoh1 gene (e.g., Hath1) in a biological cell. More specifically, the invention relates to the treatment of diseases and/or disorders that would benefit from increased Atoh1 expression, e.g., a hearing impairment or imbalance disorder associated with a loss of auditory hair cells, or a disorder associated with abnormal cellular proliferation.Type: GrantFiled: August 18, 2016Date of Patent: September 10, 2019Assignees: Massachusetts Eye & Ear Infirmary, The Brigham & Women's Hospital, Inc.Inventors: Albert Edge, Sang-Jun Jeon, Kathleen Seyb, Marcie Glicksman, Lixin Qiao, Gregory D. Cuny
-
Patent number: 10406164Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.Type: GrantFiled: February 22, 2018Date of Patent: September 10, 2019Assignee: The General Hospital CorporationInventor: David R. Elmaleh
-
Patent number: 10406165Abstract: The present invention provides modulators of protein function, to restore protein homeostasis, including GSPT1 activity. The invention provides methods of modulating protein-mediated diseases, such as GSPT1-mediated diseases, disorders, conditions, or responses. Compositions are also provided. Methods of treatment, amelioration, or prevention of protein-mediated diseases, disorders, and conditions, such as GSPT1-mediated diseases, disorders, and conditions, including cancer and astrogliosis.Type: GrantFiled: March 9, 2018Date of Patent: September 10, 2019Assignee: BioTheryX, Inc.Inventors: Kyle W. H. Chan, Paul E. Erdman, Leah Fung, Frank Mercurio, Robert Sullivan